Comments

I-MAB Stock Price, Quotes and Forecasts

Q: What sector and industry does I-MAB (IMAB) operate in?

I-MAB is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

IMABNASDAQ

Logo brought to you by Benzinga Data

Perks Buy Compare Brokers

$0.8569

-0.00960-1.11%

At close: -

$0.8700

0.011.53%

After Hours: Mar 7, 8:55 AM EDT

I-MAB (IMAB) Forecast

News Earnings I-MAB (IMAB) Options Guidance Dividends Analyst Ratings Insider Trades Short Interest

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

I-MAB Stock Price, Quotes and Forecasts | NASDAQ:IMAB | Benzinga

Explore I-MAB stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for IMAB.

Open	$0.90
Close	$0.86
Volume / Avg.	128.76K / 405.33K
Day Range	$0.84 - $0.90
52 Wk Range	0.76 - 2.00
Market Cap	$70.37M
P/E Ratio	-
Dividend Yield	-
Exchange	NASDAQ
RSI	35
Short Interest	2.87%
Days to Cover	4.14

Recent News

NVIDIA To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Monday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Avi Kapoor

I-Mab Gets New CEO After Long Search. Sale Of The Company Coming Next?

Key Takeaways: I-Mab has appointed Raj Kannan as its new CEO, filling its top position 18 months after its last top executive quit The new CEO is an industry veteran who engineered sales of his previous two companies after bringing their first drugs to market, hinting that I-Mab could follow a similar path By Warren Yang

The Bamboo Works

Short Volatility Alert: I Mab

On Wednesday, shares of I Mab (NASDAQ: IMAB) experienced volatile short activity. After the activity, the stock price went down -1.86% to $3.16. The overall sentiment for IMAB has been Bearish.

Christopher Sappo

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Analyst Trends and Forecast

Sep 24

Nov 24

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.3

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Open	$0.90
Close	$0.86
Volume / Avg.	128.76K / 405.33K
Day Range	$0.84 - $0.90
52 Wk Range	0.76 - 2.00
Market Cap	$70.37M
P/E Ratio	-
Dividend Yield	-
Exchange	NASDAQ
RSI	35
Short Interest	2.87%
Days to Cover	4.14

About I-Mab

Sector

Health Care

Industry

Biotechnology

I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in...

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

How do I buy I-MAB (IMAB) stock?

You can purchase shares of I-MAB (NASDAQ:IMAB) through any online brokerage.

View our list of the best stock brokerages

Who are I-MAB (IMAB) competitors?

Other companies in I-MAB’s space includes: Armata Pharmaceuticals (AMEX:ARMP), Citius Oncology (NASDAQ:CTOR), Inovio Pharmaceuticals (NASDAQ:INO), Vistagen Therapeutics (NASDAQ:VTGN) and Adicet Bio (NASDAQ:ACET).

What is the forecast, or price target, for I-MAB (IMAB) stock?

I-MAB has a consensus price target of $12.25.

What is the current price for I-MAB (IMAB)?

The stock price for I-MAB (NASDAQ: IMAB) is $0.87 last updated March 7, 2025 at 8:55 AM EST.

Does I-MAB (IMAB) pay a dividend?

There are no upcoming dividends for I-MAB.

When is I-MAB (NASDAQ:IMAB) reporting earnings?

I-MAB’s FY earnings are confirmed for Friday, March 21, 2025.

Is I-MAB (IMAB) going to split?

There is no upcoming split for I-MAB.

What sector and industry does I-MAB (IMAB) operate in?

I-MAB is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.